| About NicOx | |||
| Products | |||
|
Naproxcinod NCX 6560 Full portfolio |
|||
| Maximizing portfolio | |||
| Co-development Research alliances Technology |
|||
| People | |||
| Board
of Directors Management Team Contacts Careers |
|||
| Investor & media | |||
| Press
releases Investor relations Fact file Financials Corporate governance Conferences |
|||
| Home | |||
| Directions
to NicOx Site en français |
|||
| NicOx company profile | ||
| NicOx
is a product-driven biopharmaceutical company dedicated to the
development and future commercialization of investigational nitric
oxide-donating drugs to meet unmet medical needs. NicOx is applying its
proprietary nitric oxide-donating technology to develop an internal
portfolio of New Chemical Entities (NCEs) in the therapeutic areas of
inflammation and cardio-metabolic disease. Resources are focused on the development of naproxcinod, a proprietary NCE and the first member of the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with results anticipated in 2008. Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of prevalent and underserved diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD). NicOx aims to build itself into a fully integrated biopharmaceutical company through focused investment in in-house research and development programs and potentially through in-licensing and by making select acquisitions in its core therapeutic domains of inflammation and cardiometabolic disease. NicOx has strategic partnerships, collaborative agreements and research alliances with some of the world's leading pharmaceutical companies and specialist players, which allow it to maximize the value of its technology and broad portfolio, while allowing the Company to retain future commercialization rights in select areas. |
||
| Two
core therapeutic areas: inflammation and cardiometabolic Naproxcinod – Osteoarthritis NicOx' most advanced product, naproxcinod, is in phase 3 development for treating the signs and symptoms of osteoarthritis. The anti-inflammatory agents currently used in the treatment of osteoarthritis (COX-2 inhibitors and non-selective NSAIDs) have long been associated with a range of side effects, including gastrointestinal problems. Furthermore, recent clinical findings have cast significant doubt on their cardiovascular safety, including their association with increased blood pressure. Naproxcinod is a unique nitric oxide-donating anti-inflammatory and the first of the CINOD class ("COX-Inhibiting Nitric Oxide Donators"). NicOx aims to develop naproxcinod as a powerful anti-inflammatory agent with no detrimental effects on blood pressure and good gastrointestinal tolerability and safety. Top-line results from the first phase 3 study were
successful. This represents an important step towards NicOx’ goal of
making naproxcinod the drug-of-choice for osteoarthritis patients. NCX 6560 - Cardiometabolic In September 2006, NicOx selected NCX 6560 as a new
internal development candidate. NCX 6560 is a nitric oxide-donating
derivative of a commonly used statin drug, which has the potential for
broadened and increased benefit in cardiovascular disease. Statins
represent the most effective and best tolerated drugs for lowering
abnormally raised cholesterol and have consequently become the world’s
best selling class of pharmaceuticals, with combined global sales of
$20.1 billion in 2005. NCX 6560 has the potential to target
atherosclerosis and endothelial dysfunction through a multi-pathway
approach. The capacity of the nitric oxide-donating moiety to
counteract vascular inflammation and endothelial dysfunction should act
in concert with the cholesterol lowering activity of the statin
portion, to favorably influence the composition, structure and
stability of atherosclerotic plaques. |
||
| Creating Value Through Partnerships
While NicOx plans to develop its lead products internally, the Company seeks to maximize the value of its portfolio and expertise in nitric oxide-donation through major strategic partnerships and research alliances on non-core products and therapeutic areas. The
Company has research alliances with Merck & Co., Inc., Pfizer Inc
and Grupo Ferrer Internacional, S.A. and co-development agreements with
Orexo AB and TOPIGEN Pharmaceuticals Inc. |
||